Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2Phase 4 1Phase 3 1Phase 1 1

Status

Completed 37Recruiting 9Active not recruiting 8Terminated 4Unknown 2Withdrawn 1

Sponsor Class

OTHER 5INDUSTRY 4

Study Type

Interventional 8Observational 1

Sponsor

Cancer Type

Gastrointestinal 163Gynecologic 57Thoracic 39CNS 29Breast 22Other solid neoplasm 19Tumor-Agnostic 9Genitourinary 7Head & Neck 6Sarcoma 5Dermatologic 5Other hematologic neoplasm 1

Conditions

Neoplasms 7Neoplasm Metastasis 3

Interventions

pembrolizumab 26Specimen Handling 17Blood Specimen Collection 17Biopsy 16Magnetic Resonance Spectroscopy 15atezolizumab 11Surveys and Questionnaires 11Bevacizumab 9Radiotherapy 8Radiosurgery 8Nivolumab 8Fluorouracil 8Standard of Care 7Paclitaxel 7Irinotecan 7Gemcitabine 7Cisplatin 7olaparib 6durvalumab 6Palliative Care 6Oxaliplatin 6Leucovorin 6Cyclophosphamide 6Carboplatin 6Capecitabine 6alectinib 5abemaciclib 5Trastuzumab 5Interviews as Topic 5Exercise 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

9 trials
RecentStart dateEnrollment
Recruiting × Bevacizumab × Tumor-Agnostic × Clear all
NCT03899155 2026-06-03

Pan Tumor Rollover Study

Bristol-Myers Squibb

Phase 2 Recruiting
1,500 enrolled
Tumor-Agnostic

Neoplasms

NCT06551142 2026-05-22

PanTumor-101

GlaxoSmithKline

Phase 1 Recruiting
845 enrolled
Tumor-Agnostic

Neoplasms

NCT06796907 2026-05-22

BEHOLD-2

GlaxoSmithKline

Phase 1/2 Recruiting
305 enrolled
Tumor-Agnostic

Neoplasms

NCT05862285 2026-05-12

UmbrellaMAX

Hoffmann-La Roche

Phase 3 Recruiting
100 enrolled
Tumor-Agnostic

Neoplasms

NCT06031233 2026-03-30

MINUTE

Isala

Phase 4 Recruiting
776 enrolled
Tumor-Agnostic

Neoplasms

NCT06311851 2025-11-25

Transarterial Chemoembolization (TACE) Plus Bevacizumab for Liver Metastases

Pardis Noor Medical Imaging and Cancer Center

Phase 1/2 Recruiting
40 enrolled
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT05525858 2025-04-27

KOSMOSII

Seoul National University Bundang Hospital

Recruiting
1,000 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT04817956 2024-02-29

IMPRESS-N

Oslo University Hospital

Phase 2 Recruiting
3,000 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT02925234 2024-01-24

DRUP

The Netherlands Cancer Institute

Phase 2 Recruiting
1,550 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡